<DOC>
	<DOCNO>NCT01175772</DOCNO>
	<brief_summary>Preclinical study show metronomic chemotherapy induce tumor regression secondary apoptosis tumor blood vessel . This effect increase combine metronomic chemotherapy anti-angiogenic drug . Metronomic chemotherapy already prove clinical effect , especially patient breast prostate carcinoma . This study aim test efficacy experimental metronomic chemotherapy regimen cohort patient ovarian cancer . Patients receive propose regimen maintenance treatment follow response induction conventional maximal tolerate dose ( MTD ) regimen Carboplatin Paclitaxel . Our regimen include Cytophosphan combine two agent expect act indirect angiogenic inhibitor : ( ) celecoxib , selective COX-2 inhibitor ( b ) low-dose Methotrexate , successfully practice suppress inflammatory manifestation rheumatoid arthritis . All component regimen administer orally continuously one year base hypothesis anti-angiogenic property able suppress recovery residual disease , thus extend time progression ( TTP ) , possibly overall survival well .</brief_summary>
	<brief_title>Maintenance Treatment Ovarian Carcinoma Remission Antiangiogenic Treatment Strategy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>1 . Histologic proof papillaryserous ovarian cancer 1ary peritoneal carcinomatosis . 2 . Histological grade III . 3 . Original disease stage III . 4 . ECOG performance status : 02 . 5 . Age : 2080 year . 6 . Previous chemotherapy paclitaxel carboplatin ( ) . 7 . Previous cytoreductive surgery . 8 . Clinical Complete Response ( physically image ) . 9 . CA 125 either normalized ( least 50 patient ) still decrease value monthly measurement . 10 . CBC normal value toxicity grade limit I NCICCTC . 11 . Liver renal function &lt; 1.5 upper normal limit ( UNL ) SMA . 12 . The patient 's signature inform consent . 1 . Mucinous type ovarian carcinoma . 2 . Histological Grade III . 3 . Current continuous treatment steroid NSAIDs , anticoagulants `` non protocol '' reason . 4 . Previous history active peptic ulcer . 5 . Current participation treatment study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Ovary</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Maintenance</keyword>
	<keyword>Metronomic</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Time Progression</keyword>
	<keyword>overall survival</keyword>
</DOC>